Research progress on prevention strategies for immune platelet transfusion refractoriness
10.13303/j.cjbt.issn.1004-549x.2025.03.022
- VernacularTitle:免疫性血小板输注无效预防策略研究进展
- Author:
Peizhe ZHAO
1
;
Yi XU
1
;
Yajun LIANG
1
;
Qing LI
1
;
Yuan ZHOU
1
;
Xianguo XU
2
Author Information
1. Taiyuan Blood Center, Taiyuan 030024, China
2. Zhejiang Blood Center, Hangzhou 310052, China
- Publication Type:Journal Article
- Keywords:
platelet transfusion refractoriness;
immune factors;
diagnostic criteria;
prevention strategies
- From:
Chinese Journal of Blood Transfusion
2025;38(3):448-454
- CountryChina
- Language:Chinese
-
Abstract:
Platelet transfusion refractoriness (PTR) is a common issue among patients with hematological diseases and tumors. This article reviews the diagnostic criteria, influencing factors, and recent prevention and management strategies for immune PTR. The diagnostic criteria typically involve post-transfusion platelet increment (PI), platelet recovery rate (PPR), and corrected count increment (CCI). Both immune and non-immune factors can lead to PTR, with immune factors mainly including HLA and HPA antibodies. Prevention and management strategies include the use of leukocyte-reduced platelets, HLA and HPA antigen-matched platelets, intravenous immunoglobulin therapy, and immunosuppressive strategies. Although various strategies have been proposed and applied in clinical practice, the prevention and management of immune PTR remain challenging. Future research needs to explore more effective individualized treatment strategies, while also considering the potential application of emerging technologies such as nanotechnology in the field of transfusion.
